31 Jul 2014 13:51
31 July 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, will announce its interim results for the six months ended 30 June 2014, on Friday 8 August 2014. PuriCore will also host a conference call for analysts and investors at 2pm BST (9 am EST). To participate, please use the conference call details below:
From the UK: +44 (0)20 3139 4830
From the US: +1 718.873.9077
Pin code: 67258174#
A recording of the call will be archived on the Company's website at investor.puricore.com/events.
Enquiries:
UK | US |
FTI Consulting | Sage Strategic Marketing |
Mo Noonan/Simon Conway | Jennifer Guinan |
Victoria Foster Mitchell | +1 610.410.8111 |
+44 203 727 1000 | jennifer@sagestrat.com |
About PuriCore
PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in a well-established core business and emerging sectors of two broad markets: Food & Agriculture and Health Sciences. In the Food & Agriculture market, PuriCore's portfolio is used by thousands of US supermarket retailers, including three of the top-five, to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In the Health Sciences market, PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. PuriCore is headquartered in Malvern, Pennsylvania. To receive additional information on PuriCore, visit www.puricore.com.